미래의 항우울제

참고문헌 (81)

1. Kessler RC, "Prevalence,severity,and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication", Arch Gen Psychiatry, 62, pp.617~627 (2005)
2. Murray CJ, "Evidence-based health policy--lessons from the Global Burden of Disease Study", Science, 274, pp.740~743 (1996)
3. Greenberg PE, "The economic burden of depression in the United States:how did it change between 1990 and 2000", J Clin Psychiatry, 64, pp.1465~1475 (2003)
4. World Health Organization, "The world health report 2001-Mental Health: New understanding" (2001), New Hope
5. Wells KB, "The functioning and well-being of depressed patients.Results from the Medical Outcomes Study", JAMA, 262, pp.914~919 (1989)
6. Guze SB, "Suicide and primary affective disorders", The Br J Psychiatry, 117, pp.437~438 (1970)
7. Weissman MM, "Cross-national epidemiology of major depression and bipolar disorder", JAMA, 276, pp.293~299 (1996)
8. Fava M, "Major depressive disorder", Neuron, 28, pp.335~341 (2000)
9. Burmeister M, "Basic concepts in the study of diseases with complex genetics", Biol Psychiatry, 45, pp.522~532 (1999)
10. McEwen BS, "Neurobiology of mood,anxiety,and emotions as revealed by studies of a unique antidepressant:tianeptine", Mol Psychiatry, 10, pp.525~537 (2005)
11. Hirschfeld RM, "History and evolution of the monoamine hypothesis of depression", J Clin Psychiatry, 61, pp.4~6 (2000)
12. Pacher P, "Trends in the development of new antidepressants", Is there a light at the end of the tun-nel? Curr Med Chem, 11, pp.925~943 (2004)
13. Rush AJ, "Bupropion-SR,sertraline,or venlafaxine-XR after failure of SSRIs for depression", N Engl J Med, 354, pp.1231~1242 (2006)
14. Trivedi MH, "Medication augmentation after the failure of SSRIs for depression", N Engl J Med, 354, pp.1243~1252 (2006)
15. Baudry A, "New views on antidepressant action", Curr Opin Neurobiol, 21, pp.1~8 (2011)
16. Chang T, "The future of psychopharmacology of depression", J Clin Psychiatry, 71, pp.971~975 (2010)
17. Korte SM, "The Darwinian concept of stress:benefits of allostasis and costs of allostatic load and the trade-offs in health and disease", Neurosci Biobehav Rev, 29, pp.3~38 (2005)
18. Dranovsky A, "Hippocampal neurogenesis:regulation by stress and antidepressants", Biol Psychiatry, 59, pp.1136~1143 (2006)
19. Bissette G, "Elevated concentrations of CRF in the locus coeruleus of depressed subjects", Neuropsychopharmacology, 28, pp.1328~1335 (2003)
20. Bale TL, "CRF and CRF receptors:role in st-ress responsivity and other behaviors", Annu Rev Pharmacol Toxicol, 44, pp.525~557 (2004)
21. Charmandari E, "Endocrinology of the stress response", Annu Rev Physiol, 67, pp.259~284 (2005)
22. Gillespie CF, "Hypercortisolemia and depression", Psychosom Med, 67, pp.S26~S28 (2005)
23. Keck ME, "Listening to mutant mice:a spotlight on the role of CRF", CRF receptor systems in affective disorders, 2005, pp.29, 867~889
24. Liapakis G, "Members of CRF family and their receptors: from past to future", Curr Med Chem, 18, pp.2583~2600 (2011)
25. Zobel AW, "Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression:the first 20 patients treated", J Psychi atr Res, 34, pp.171~181 (2000)
26. Schulz DW, "CP-154,526:a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors", Proc Natl Acad Sci U S A, 93, pp.10477~10482 (1996)
27. Holsboer F, "Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists", Eur J Pharmacol, 583, pp.350~357 (2008)
28. Zorrilla EP, "Progress in corticotropin-releasing factor-1 antagonist development", Drug Discov Today, 15, pp.371~383 (2010)
29. Li YW, "The pharmacology of DMP696 and DMP904,non-peptidergic CRF1 receptor antagonists", CNS Drug Rev, 11, pp.21~52 (2005)
30. de Kloet ER, "Stress and the brain:from adaptation to disease", Nat Rev Neurosci, 6, pp.463~475 (2005)
31. Sapolsky RM, "Stress hormone:good and bad", Neurobiol Dis, 7, pp.540~542 (2000)
32. Flores BH, "Clinical and biological effects of mifepristone treatment for psychotic depression", Neuropsychopharmacology, 31, pp.628~636 (2006)
33. Blasey CM, "A multisite trial of mifepristone for the treatment of psychotic depression:a site-by-treatment interaction", Contemp Clin Trials, 30, pp.284~288 (2009)
34. Blasey CM, "Efficacy and safety of mifepristone for the treatment of psychotic depression", J Clin Psychopharmacol, 31, pp.436~440 (2011)
35. Jahn H, "Metyrapone as additive treatment in major depression:a double-blind and placebo-controlled trial", Arch Gen Psychiatry, 61, pp.1235~1244 (2004)
36. Boyle MP, "Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior", Proc Natl Acad Sci U S A, 102, pp.473~478 (2005)
37. Wei Q, "Glucocorticoid receptor overexpression in forebrain:a mouse model of increased emotional lability", Proc Natl Acad Sci U S A, 101, pp.11851~11856 (2004)
38. Keck ME, "Reduction of hypothalamic vasopressinergic hyperdrive contributes to clinically relevant behavioral and neuroendocrine effects of chronic paroxetine treatment in a psychopathological rat model", Neuropsychopharmacology, 28, pp.235~243 (2003)
39. Breuer ME, "SSR149415,a non-peptide vasopressin V1b receptor antagonist,has long-lasting antidepressant effects in the olfactory bulbectomy-induced hyperactivity depression model", Naunyn Schmiedebergs Arch Pharmacol, 379, pp.101~106 (2009)
40. Wersinger SR, "Vasopressin V1b receptor knockout reduces aggressive behavior in male mice", Mol Psychiatry, 7, pp.975~984 (2002)
41. Duman RS, "A neurotrophic model for stress-related mood disorders", Biol Psychiatry, 59, pp.1116~1127 (2006)
42. Chen B, "Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication", Biol Psychiatry, 50, pp.260~265 (2001)
43. Shirayama Y, "Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression", J Neurosci, 22, pp.3251~3261 (2002)
44. Monteggia LM, "Essential role of brain-derived neurotrophic factor in adult hippocampal function", Proc Natl Acad Sci U S A, 101, pp.10827~10832 (2004)
45. Eisch AJ, "Brain-derived neurotrophic factor in the ventral midbrain-nucleus accumbens pathway:a role in depression", Biol Psychiatry, 54, pp.994~1005 (2003)
46. Berton O, "Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress", Science, 311, pp.864~868 (2006)
47. Turner CA, "The fibroblast growth factor system and mood disorders", Biol Psychiatry, 59, pp.1128~1135 (2006)
48. Duman RS, "Role of neurotrophic factors in the etiology and treatment of mood disorders", Neuromolecular Med, 5, pp.11~25 (2004)
49. Simen BB, "TNFalpha signaling in depression and anxiety:behavioral consequences of individual receptor targeting", Biol Psychiatry, 59, pp.775~785 (2006)
50. Schmidt HD, "Future Antidepressant Targets:Neurotrophic Factors and Related Signaling Cascades", Drug Discov Today Ther Strateg, 5, pp.151~156 (2008)
51. Palucha A, "On the role of metabotropic glutamate receptors in the mechanisms of action of antidepressants", Pol J Pharmacol, 54, pp.581~586 (2002)
52. Cameron HA, "Regulation of ad-ult neurogenesis by excitatory input and NMDA receptor activation in the dentate gyrus", J Neurosci, 15, pp.4687~4692 (1995)
53. Paul IA, "Glutamate and depression:clinical and preclinical studies", Ann N Y Acad Sci, 1003, pp.250~272 (2003)
54. Sanacora G, "Clinical studies implementing glutamate neurotransmission in mood disorders", Ann N Y Acad Sci, 1003, pp.292~308 (2003)
55. Zarate CA Jr, "A double-blind,placebo-controlled study of memantine in the treatment of major depression", Am J Psychiatry, 163, pp.153~155 (2006)
56. Bonanno G, "Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus", J Neurosci, 25, pp.3270~3279 (2005)
57. Duman RS, "Signaling pathways underlying the rapid antidepressant actions of ketamine" (2011), Neuropharmacology. In press
58. Autry AE, "NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses", Nature, 15(475), pp.91~95 (2011)
59. Miyamoto Y, "Lower sensitivity to stress and altered monoaminergic neuronal function in mice lacking the NMDA receptor epsilon 4 subunit", J Neurosci, 22, pp.2335~2342 (2002)
60. Alt A, "AMPA receptor potentiators as novel antidepressants", Curr Pharm Des, 11, pp.1511~1527 (2005)
61. Bergstrom M, "Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant", Biol Psychiatry, 55, pp.1007~1012 (2004)
62. Hargreaves R, "Imaging substance P receptors(NK1)in the living human brain using positron emission tomography", J Clin Psychiatry, 63, pp.18~24 (2002)
63. Adell A, "Antidepressant properties of substance P antagonists:relationship to monoaminergic mechanisms", Curr Drug Targets CNS Neurol Disord, 3, pp.113~121 (2004)
64. Rupniak NM, "Comparison of the phenotype of NK1R-", -mice with pharmacological blockade of the substance P(NK1)receptor in assays for antidepressant and anxiolytic drugs, 2001, pp.12, 497~508
65. Kramer MS, "Distinct mechanism for antidepressant activity by blockade of central substance P receptors", Science, 281, pp.1640~1645 (1998)
66. Adell A, "Strategies for producing faster acting antidepressants", Drug Discov Today, 10, pp.578~585 (2005)
67. Kramer MS, "Distinct mechanism for antidepressant activity by blockade of central substance P receptors", Science, 281, pp.1640~1645 (1998)
68. Blier P, "Impact of substance P receptor antagonism on the serotonin and norepinephrine systems:relevance to the antidepressant", anxiolytic response, 2004, pp.29, 208~218
69. Musazzi L, "Ch-anges in signaling pathways regulating neuroplasticity induced by neurokinin 1 receptor knockout", Eur J Neurosci, 21, pp.1370~1378 (2005)
70. van der Hart MG, "Chronic psychosocial stress in tree shrews:effect of the substance P(NK1 receptor)an-tagonist L-760735 and clomipramine on endocrine and behavioral parameters", Psychopharmacology, 181, pp.207~216 (2005)
71. Ryckmans T, "First dual NK(1)antagonists-serotonin reuptake inhibitors:synthesis and SAR of a new class of potential antidepressants", Bioorg Med Chem Lett, 12, pp.261~264 (2002)
72. Ebner K, "The role of substance P in stress and anxiety responses", Amino Acids, 31, pp.251~272 (2006)
73. Hebenstreit GF, "Rolipram in major depressive disorder:results of a double-blind comparative study with imipramine", Pharmacopsychiatry, 22, pp.156~160 (1989)
74. Itoh T, "Effects of rolipram,a pho-sphodiesterase 4 inhibitor,in combination with imipramine on depressive behavior,CRE-binding activity and BDNF level in learned helplessness rats", Eur J Pharmacol, 498, pp.135~142 (2004)
75. Xiao L, "Effects of re peated treatment with phosphodiesterase-4 inhibitors on cAMP signaling,hippocampal cell proliferation,and behavior in the forced-swim test", J Pharmacol Exp Ther, 338, pp.641~647 (2011)
76. Tully T, "Targeting the CREB pathway for memory enhancers", Nat Rev Drug Discov, 2, pp.267~277 (2003)
77. Carlezon WA Jr. Duman RS, "The many faces of CREB", Trends Neurosci, 28, pp.436~445 (2005)
78. Ramos BP, "Dysregulation of protein kinase a signaling in the aged prefrontal cortex:new strategy for treating age-related cognitive decline", Neuron, 40, pp.835~845 (2003)
79. Tsigos C, "Hypothalamic-pituitary-adrenal axis,neuroendocrine factors and stress", J Psychosom Res, 53, pp.865~871 (2002)
80. Ramamoorthy S, "Regulation of the human serotonin transporter by interleukin-1 beta", Biochem Biophys Res Commun, 216, pp.560~567 (1995)
81. Dantzer R, "From inflammation to sickness and depression:when the immune system subjugates the brain", Nat Rev Neurosci, 9, pp.46~56 (2008)

관련 논문AI추천